Core Insights - The article highlights the recent A+ round financing of Suzhou Zhongxi Biological Information Co., Ltd. (Zhongxi Bio), which raised several million yuan, primarily aimed at enhancing its AI models and algorithms, as well as upgrading its automation workstation and instrument product lines [2][3]. Group 1: Financing and Growth - Zhongxi Bio has successfully completed four rounds of financing since 2023, with the latest round occurring just six months after the previous one in July 2025, indicating strong capital recognition and validation of its "smart laboratory" ecosystem strategy [3]. - The continuous success in financing is attributed to Zhongxi Bio's unique strategic positioning and clear commercialization path, focusing on a development model that integrates AI, automation equipment, and fully autonomous manufacturing [6]. Group 2: Strategic Transformation - Zhongxi Bio is transitioning from a single equipment supplier to a "smart laboratory" ecosystem builder, collaborating with industry leaders to create replicable "smart laboratory units," which enhances the integration of technology with specific scenarios [6]. - The founder of Zhongxi Bio, Zhu Bin, emphasizes that true intelligence goes beyond merely replacing human labor; it involves deep AI empowerment to reshape research and improve product quality and stability, enabling high-quality scaling [6]. Group 3: Innovation and Technology - The core innovation of Zhongxi Bio's "smart laboratory" system lies in constructing a closed-loop of "AI agents + automated experimental platforms," providing comprehensive intelligent support for research from hypothesis generation to experimental optimization [6]. - This system aims to establish a "data-driven - autonomous decision-making - cyclical evolution" framework, allowing laboratories to continuously self-optimize [6].

Core Viewpoint - Qingfeng Biotech has completed a multi-million Pre-A round financing, led by Baiyun Fund, to advance its AI+ laboratory automation initiatives, including capacity expansion and the development of AI models [1] Market Status - The laboratory automation market is entering a stable growth phase, with AI becoming a key driver. The global market size is projected to reach approximately $8-8.3 billion in 2024, $9 billion in 2025, and $14-18 billion by 2030, maintaining a compound annual growth rate (CAGR) of 7-9% [2] - In China, the AI-related laboratory market is expected to grow from approximately 15-20 billion RMB in 2024 to 20-25 billion RMB in 2025, and reach 50-60 billion RMB by around 2030, with a CAGR of 15-20% [4] Company Overview - Qingfeng Biotech, established in 2018, focuses on the R&D, production, and sales of life science automation equipment and integrated platforms. The company emphasizes system-level design and platform delivery capabilities rather than just single-device solutions [5] - The OutStanding large-scale automated pipetting workstation integrates high flexibility, modularity, and standardization, supporting multiple life science applications. It has successfully bid for a project valued at nearly 2 million RMB per unit, competing with imported brands [5] AI Integration - Qingfeng Biotech is enhancing its laboratory automation applications by integrating AI capabilities, focusing on the development of BioFlow AI and Supervisor AI models for experimental process management and data-driven optimization [6] - The trend of "AI+ smart laboratories" is evolving from single-point algorithms to core capabilities throughout the entire experimental process, aiming to reduce human error and improve operational efficiency [7] Post-Financing Strategy - The company's development focus is shifting from individual equipment to a systematic construction of "automation platforms + AI capabilities." The financing will be directed towards capacity, algorithms, application centers, and platform capabilities, highlighting the importance of scalable delivery and long-term technological evolution [8]